Abbott and Reata Pharmaceuticals announce agreement to develop
Abbott and Reata Pharmaceuticals recently announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl, which is currently in late Phase 2 trials for the treatment of chronic kidney disease.
Abbott Laboratories announced plans to split into two publicly traded companies -- one in diversified medical products and the other in research-based pharmaceuticals, marking a significant change in the company's 123-year history.